Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: A very long-term follow-up

Cerebrovascular Diseases

Volumn 37, Issue 3, 2014, Pages 181-187

  Alvarez Sabín, José ^a   Quintana, Manuel ^a   Santamarina, Estevo ^a   Maisterra, Olga ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Antiplatelet treatment; Aspirin; Hemorrhagic risk; Secondary prevention of stroke; Stroke recurrence; Triflusal

Indexed keywords

ACETYLSALICYLIC ACID; TRIFLUSAL; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; UPPER GASTROINTESTINAL BLEEDING; ATHEROTHROMBOTIC ISCHEMIC STROKE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; HEADACHE; HOSPITAL; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

AGED; ASPIRIN; BRAIN ISCHEMIA; DYSPEPSIA; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; INTRACRANIAL ARTERIOSCLEROSIS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PLATELET AGGREGATION INHIBITORS; RECURRENCE; SALICYLATES; SECONDARY PREVENTION; VASCULAR DISEASES;

EID: 84893638357     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000357662     Document Type: Article

References (48)

1. Antithrombotic Trialists Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J 2002; 324: 71-86.
2. Antithrombotic Trialists (ATT) Collaboration: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849-1860.
3. Culebras A, Borja J, Garcia-Rafanell J: Triflusal versus aspirin for the prevention of stroke. Prog Neurother Neuropharmacol 2008; 3: 13-33.
4. Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, et al: Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2002; 21: 457-465.
5. Matias-Guiu J, Alvarez-Sabin J, Codina A: Estudio comparativo del efecto del acido acetilsalicilico en dosis bajas y el triflusal en la prevencion de eventos cardiovasculares en adultos jovenes con enfermedad cerebrovascular isquemica. Rev Neurol 1997; 25: 1669-1672.
6. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, et al; TACIP investigators: Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP study: a randomized, double-blind, multicenter trial. Stroke 2003; 34: 840-848.
7. Culebras A, Rotta-Escalante R, Vila J, et al; TAPIRSS Investigators: Triflusal vs aspirin for prevention of cerebral infarction. Neurology 2004; 62: 1073-1080.
8. Costa J, Ferro JM, Matias-Guiu J, Alvarez-Sabin J, Torres F: Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; 3:CD004296.
9. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis 2008; 25: 457-507.
10. Flynn RWV, MacDonald TM, Murray GD, MacWalter RS, Doney ASF: Persistence, adherence and outcomes with antiplatelet regimens following cerebral infarction in the Tayside stroke cohort. Cerebrovasc Dis 2012; 33: 190-197.
11. Weimar C, Cotton D, Sha N, et al: Discontinuation of antiplatelet study medication and risk of recurrent stroke and cardiovascular events: results from the PRoFESS study. Cerebrovasc Dis 2013; 35: 538-543.
12. Alvarez Sabin J, Molina C, Martin R, Matias-Guiu J: Tolerancia de dos pautas de tratamento de triflusal en pacientes con ictus isquemico. Rev Neurol 1996; 24: 1306-1307.
13. Acheson J, Danta G, Hutchinson C: Controlled trial of dipyridamole in cerebral vascular disease. Br Med J 1969; 1: 614-1615.
14. The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-59.
15. Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia (AITIA study). Thromb Haemost 1979; 28: 135-141.
16. Guiraud B, David J, Geraud G, Boneu B, Bierme R, Rascol A: Prevention of ischemic cerebro vascular accident: a long-term clinical trial with vasodilator and antiaggregatin drugs. Thromb Diath Haemorrh 1975; 34: 343-344.
17. Bousser MG, Eschwege E, Haguenau M, Lefaucconnier JM, Touboul D, Touboul PJ: AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14: 5-14.
18. Candelise L, Landi G, Perrone P, Bracchi M, Brambilla G: A randomized trial of aspirin and sulfinpyrazone in patients with TIA. Stroke 1982; 13: 175-179.
19. Sorensen PS, Pedersen H, Marquardsen J, et al: Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke 1983; 14: 15-22.
20. The American-Canadian Co-operative Group: Persantine Aspirin Trial in cerebral ischemia. II. Endpoint results. Stroke 1985; 16: 406-415.
21. A Swedish Cooperative Study: High-dose acetylsalicylic acid after cerebral infarction. Stroke 1987; 18: 325-334.
22. Peto R, Gray R, Collins R, et al: Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988; 296: 313-316.
23. The ESPS Group: The European Stroke Prevention Study (ESPS). Principal end-points. Lancet 1987; 2: 1351-1354.
24. UK-TIA Study Group: The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044-1054.
25. Steering Committee of the Physicians Health Study Research Group: Final report of the aspirin component of the ongoing physicians health study. N Engl J Med 1989; 321: 129-135.
26. Matias-Guiu J, Davalos A, Pico M, Monasterio J, Vilaseca J, Codina A: Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks. Acta Neurol Scand 1987; 76: 413-421.
27. Boysen G, Sorensen PS, Juhler M, et al: Danish very-low-dose aspirin after carotid endarterectomy trial. Stroke 1988; 19: 1211-1215.
28. Hass WK, Easton JD, Adams HP Jr, et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321: 501-507.
29. Gent M, Blakely JA, Easton JD, et al: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
30. The SALT Collaborative Group: Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338: 1345-1349.
31. The Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325: 1261-1266.
32. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.
33. Bergamasco B, Benna P, Carolei A, Rasura M, Rudelli G, Fieschi C: A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Funct Neurol 1997; 12: 33-43.
34. CAPRIE Steering Committee: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
35. Gotoh F, Tohgi H, Hirai S, et al: Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000; 9: 147-157.
36. Lee TK, Chan KWA, Huang ZS, Sien-Kiat SG, Lin RT, Po HL: Effectiveness of low-dose ASA in prevention of secondary ischemic stroke; the ASA Study Group in Taiwan. Thromb Res 1997; 87: 215-224.
37. Steiner M, Glantz M, Lekos A: Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995; 62(suppl):1381S-1384S.
38. Ito E, Takahashi A, Yamamoto H, Kuzuhara S, Uchiyama S, Nakajima M: Ticlopidine alone versus ticlopidine plus aspirin for preventing recurrent stroke. Tokai Panaldine Aspirin Long-Term Study (TOPALS). Intern Med 2003; 42: 793-799.
39. Gorelick PB, Richardson DJ, Kelly M, et al; African American Antiplatelet Stroke Prevention Study Investigators: Aspirin and ticlopidine for prevention of recurrent stroke in black patients. JAMA 2003; 289: 2947-2957.
40. The ESPRIT Study Group: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-1673.
41. Diener HC, Bogousslavsky J, Brass LM, et al; MATCH Investigators: Aspirin and clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
42. Shinohara Y, Nishimaru K, Sawada T, et al; S-ACCESS Study Group: Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): a randomized, double-blind, aspirin-controlled trial. Stroke 2008; 39: 1827-1833.
43. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
44. Sacco RL, Diener HC, Yusuf S, et al; PRoFESS Study Group: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359: 1238-1251.
45. Huang Y, Cheng Y, Wu J, et al; Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention Cooperation Investigators: Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 494-499.
46. McQuaid KR, Laine L: Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119: 624-638.
47. Ibanez L, Vidal X, Vendrell L, Moretti U, Laporte JR: Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther 2006; 23: 235-242.
48. Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R: Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal antiinflammatory drugs. Eur J Gastroenterol Hepatol 2003; 15: 173-178.